

ADHD Guideline Committee Meeting 11

Date and Time: Tuesday 11 April 2017, 10:00-16:00

Place: Boardroom, National Guideline Centre

Minutes: Confirmed

Present:

Gillian Baird (GB)	Professor of Paediatric Neurodisability and Consultant Developmental Paediatrician, Chair
Emily Simonoff (ES)	Professor of Child & Adolescent Psychiatry, Clinical Specialist
Marios Adamou (MA)	Consultant Psychiatrist (adults) and Visiting Professor
Philip Asherson (PA)	Professor of Psychiatry and Honorary Consultant Psychiatrist
Poppy Ellis Logan (PEL)	Lay Member
Jean Fitzpatrick (JF)	Lay Member
Gisli Gudjonsson (GG)	Professor of Psychology
Chris Hollis (CH)	Professor of Child & Adolescent Psychiatry and Consultant in Developmental Neuropsychiatry
Nicole Horwitz (NH)	Consultant Community Paediatrician
Karen Pratt (KP)	Paediatric Nurse Specialist for Neurodisability
Kapil Sayal (KS)	Professor of Child & Adolescent Psychiatry and Honorary Consultant Psychiatrist
David Traxson (DT)	Educational Psychologist
Jody Warner-Rogers (JWR)	Consultant Clinical Psychologist and Paediatric Neuropsychologist
Ian Wong (IW)	Professor of Pharmacy Practice and Medicine Evaluation

NICE team

Ben Doak (BD)	Guidelines Commissioning Manager
---------------	----------------------------------

NGC technical team

Katie Broomfield (KB)	Document Editor/Process Assistant (notes)
Margaret Constanti (MC)	Senior Health Economist
James Gilbert (JG)	Senior Research Fellow
Kate Kelley (KK)	Guideline Lead
Rafina Yarde (RY)	Research Fellow

Apologies

Alex Allen (AA)	Senior Research Fellow
Joanna Ashe (JA)	Senior Information Specialist, NGC

Rebecca Boffa (RB)	Research Fellow, NGC
Polly Branney (PB)	General Practitioner
Samantha Jones (SJ)	Project Manager, NCG
Jen Lewis-Neill (JLN)	Clinical Lead/Independent Nurse Prescriber
Jonathan Rackham (JR)	Lay Member

Notes

1. The Chair welcomed the group to the eight meeting of this GC. Apologies were received from AA, JA, RB, PB, SJ, JLN and JR.
2. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to previous declarations recorded in the DOI register, for this meeting, no action applies. The following new declarations were received for this meeting:

GC Declarations of Interest			
N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
PA	<ol style="list-style-type: none"> 1. Attended UKAAN consensus meeting designed to generate a consensus on the role of occupational therapy in the diagnosis and treatment of adults with ADHD. No fees or costs involved. 2. Speaker at Shire sponsored training event to adult mental health practitioners. The talk was on the diagnosis of ADHD in the presence of co-existing disorders and did not discuss treatment of ADHD. A speaker fee was paid to King's College London. 3. Took part in a filmed webinar in which I described how to differentiate ADHD in adults from other conditions. The film was taken by the education service Peer Voice for which they paid a fee for my time and contribution to King's College London. 4. Took part in a service user conference organised by ADDISS. My talk was on the role of mind wandering in ADHD. No fees or costs were involved. 5. Delivered a training day to adult psychiatrists on the diagnosis of ADHD and differentiation from adult mental health disorders, as part of the UKAAN training for 	<ol style="list-style-type: none"> 1. Personal non-financial specific 2. Non-personal financial specific 3. Non-personal financial specific 4. Personal non-financial specific 5. Non-personal financial specific 6. Personal non-financial specific 	<ol style="list-style-type: none"> 1. Declare and participate 2. Declare and participate 3. Declare and participate 4. Declare and participate 5. Declare and participate 6. Declare and participate

	<p>adult mental health professionals. A trainers fee was paid to King's College London.</p> <p>6. Attended the European Psychiatric Association (EPA: 1/4/17 – 3/4/17) to give several talks and education sessions: a treatment trial of cannabinoids in ADHD; ADHD across the lifespan; the aetiology of ADHD across the lifespan; a poster on health utilities in a survey sample of ADHD. Travel and hotel costs were paid for by EPA. No other payments were received.</p>		
PEL	<ol style="list-style-type: none"> Contributed content for University/College issues information/advice on AADD-UK page. Unpaid. Planning an awareness raising campaign about ADHD provision in the UK (#Attention UK). Unpaid. Invited to join #BorntobeADHD committee as a lay member. Unpaid. 	<ol style="list-style-type: none"> Personal non-financial specific Personal non-financial specific Personal non-financial specific 	<ol style="list-style-type: none"> Declare and participate Declare and participate Declare and participate
CH	<ol style="list-style-type: none"> Paper currently under review for diagnostic assessment using Qb test. Was invited to present at the World ADHD Congress in Vancouver, Canada 20-23 April 2017. Usual expenses only, no fee paid. 	<ol style="list-style-type: none"> Personal non-financial non-specific Personal non-financial specific 	<ol style="list-style-type: none"> Declare and participate Declare and participate
KS	<p>Author on a review paper on "ADHD in children and young people: prevalence, care pathways and service provision" accepted for publication by the Lancet Psychiatry. An honorarium will be paid to KS' department.</p>	<p>Non-personal financial specific</p>	<p>Declare and participate</p>
<p>NICE DOI policy classifications are:</p> <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific • Personal non-financial specific • Personal non-financial non-specific • Non-personal financial specific • Non-personal financial non-specific 			

- The meeting notes and NICE minutes of the last meeting were reviewed by the committee. No amendments were required. The notes and NICE minutes were then agreed as a true and accurate record of the meeting.
- JG discussed the updates to the non-pharma efficacy review with the committee.
- JG led a discussion on the clinical evidence for the combination review. MC presented the economic evidence and possible areas for economic modelling. The group discussed

- recommendations and agreed areas for economic modelling.
6. AOB: Action points were assigned and next steps discussed.

Date, time and venue of the next meeting

Committee Meeting 12: Tuesday 23 May, 10:00-16:00, NGC Boardroom, 180 Great Portland Street, London W1W 5QZ